ArticleJACC. Advances2026
Assisted Reproductive Technology for Adults With Congenital and Acquired Heart Disease.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Women's Cardiovascular Health: Progress, Gaps, and the Road Ahead.JACC. Advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAssisted reproductive technology (ART) is increasingly used by individuals with cardiovascular disease (CVD) to achieve pregnancy.
objectivesThe objective of the study was to compare adverse cardiovascular, obstetric, and neonatal events in individuals with CVD who conceived using ART vs age-matched controls who conceived spontaneously.
methodsRetrospective analysis of the Standardized Outcomes in Reproductive Cardiovascular Care cohort from November 2011 to December 2024. Pregnancies conceived using ART were matched 2:1 with spontaneous conceptions in individuals with congenital or acquired CVD. An exploratory analysis for short-term safety and efficacy was performed in those who received ART at the primary center.
resultsThe cohort included 100 pregnancies conceived with ART and 200 spontaneous pregnancies, followed for 1-year postpartum. There were no significant differences in congestive heart failure (4% vs 4%, P = 1.0) and sustained arrhythmia (9% vs 6%, P = 0.34). With respect to obstetric and neonatal outcomes, there was no difference in hypertensive disorders of pregnancy (21% vs 15%, P = 0.20), preterm birth (11% vs 13%, P = 0.85), birthweight (3.2 kg vs 3.1 kg, P = 0.40), or need for neonatal intensive unit admission (32% vs 22%, P = 0.13). In a subset of the population receiving ART at our institution (n = 41 subjects undergoing 57 in vitro fertilization cycles), there were 15 median oocytes per retrieval. There were 85 embryo transfers with an implantation rate of 56.2% and live birth rate of 57.7%.
conclusionsIn individuals with CVD, pregnancy outcomes following ART were comparable to those with spontaneous conception, supporting the safety of ART in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.